Tropifexor, also known as LJN452, is a highly potent hammerhead type FXR agonist that is currently under clinical trials for NASH and PBC patients (Kremoser, 2021; Sanyal et al., 2023; Tully et al., 2017). Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.